WAINUA™ (eplontersen) Granted First-Ever Regulatory A

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , American , America , Isabelle Lousada , Brendan Mcevoy , Michaelj Polydefkis , Chelsea Tressler , European Parliament , Commission Implementing Decision , Columbia University Irving Medical Center , Ionis Pharmaceuticals , Astrazeneca , Drug Administration , Amyloidosis Research Consortium , European Commission , Journal Of The American Medical Association , Neuropathy Impairment Score , Norfolk Quality , Life Questionnaire Diabetic Neuropathy , American Medical Association , Johns Hopkins University School , Executive Vice President , Biopharmaceuticals Business Unit , Latin America , Orphan Drug Designation , Serum Vitamin , Recommended Supplementation , Prescribing Information , Rare Diseases , Hereditary Transthyretin Amyloidosis With , Annual Report , Clin Risk , Global Phase , Antisense Oligonucleotide , Hereditary Transthyretin Mediated Amyloid , Neurol Neurosurg , Open Label Phase , University Irving Medical Center , Drug Reduces Death , Underdiagnosed Form , Heart Failure ,